The Prevention of Hypotension After Epidural Analgesia After Major Surgery

Sponsor
University of Florida (Other)
Overall Status
Completed
CT.gov ID
NCT02722746
Collaborator
I. Heermann Anesthesia Foundation (Other)
66
1
3
21.9
3

Study Details

Study Description

Brief Summary

Epidural analgesia via continuous epidurally infused local anesthetic agent (LA) is widely and very successfully used routinely for perioperative pain control in patients undergoing major orthopedic and abdominal surgery since 1928. The choice currently depends on the preference of the APS physician in charge of the case. A frequent unwanted side effect of epidural block is hypotension due to the epidurally injected LA blocking the sympathetic nerves and thus the patient's response to hypotension, which is usually due to hypovolemia and/or an unopposed parasympathetic (via the vagus nerve) nervous system. The purpose of this research study is to see if adding epinephrine, to the epidural anesthetic will decrease possible side effects, such as low blood pressure, and lead to a better effect of the epidural anesthetic.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Participants undergoing epidural analgesia to treat perioperative pain associated with major surgery will be approached for their willingness to participate in the study. Participants undergoing major thoracic, abdominal, or orthopaedic surgery for whom thoracic or lumbar epidural block would be indicated and planned for intraoperative and postoperative analgesia as per the University of Florida Acute Pain Service (APS) usual and routine practice will be included in this study.

All participants will receive a standardized continuous epidural block at the appropriate level for the planned surgery by the APS physicians in the block room that day. For the standardized continuous epidural block, placement will be confirmed with loss of resistance technique (LORA), wave form analysis or nerve stimulation.

Participants will be randomly allocated by computer-generated randomization to one of four groups. This will be a quintuple blinded prospective study. The anesthesiologist managing the intraoperative anesthesia, the anesthesiologists (APS) placing the blocks and following the participants on the floors, the research nurse taking the measurement, the surgeons, nor the participants will be aware of what combination of drugs are used for the epidural block infusion.

The three groups will consist of:
  1. Group A (Ropivacaine 0.2% infusion; Control group)

  2. Group B (Ropivacaine 0.2% + 2 mcg/mL epinephrine)

  3. Group C (Ropivacaine 0.2% + 5 mcg/mL epinephrine)

Study Design

Study Type:
Interventional
Actual Enrollment :
66 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Basic Science
Official Title:
The Prevention of Hypotension After Epidural Analgesia After Major Surgery by Adding Epinephrine to Infusions to Counteract Sympathectomy: a Double- Blind, Controlled, Randomized, Prospective Dose-finding Study
Actual Study Start Date :
Nov 15, 2016
Actual Primary Completion Date :
Oct 4, 2017
Actual Study Completion Date :
Sep 14, 2018

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Ropivacaine only Control group

The participants in this group will receive standard anesthesia, epidural analgesia with 0.2% ropivacaine with no epinephrine added during the procedure.

Drug: Ropivacaine
Epidural block infusion with Ropivacaine 0.2% will be provided as the anesthesia per standard of care during the procedure.
Other Names:
  • Naropin
  • Active Comparator: Ropivacaine + 2 mcg/mL epinephrine

    The participants in this group will receive standard anesthesia (Ropivacaine 0.2%) with the addition of 2mcg/mL of epinephrine during the procedure.

    Drug: Ropivacaine
    Epidural block infusion with Ropivacaine 0.2% will be provided as the anesthesia per standard of care during the procedure.
    Other Names:
  • Naropin
  • Drug: Epinephrine
    Participants will receive epinephrine in their epidural block infusion during the procedure. The amount of epinephrine provided during the procedure will be based on the group assignment.
    Other Names:
  • Adrenalin
  • Active Comparator: Ropivacaine + 5 mcg/mL epinephrine

    The participants in this group will receive standard anesthesia (Ropivacaine 0.2%) with the addition of 5mcg/mL of epinephrine during the procedure.

    Drug: Ropivacaine
    Epidural block infusion with Ropivacaine 0.2% will be provided as the anesthesia per standard of care during the procedure.
    Other Names:
  • Naropin
  • Drug: Epinephrine
    Participants will receive epinephrine in their epidural block infusion during the procedure. The amount of epinephrine provided during the procedure will be based on the group assignment.
    Other Names:
  • Adrenalin
  • Outcome Measures

    Primary Outcome Measures

    1. Changes between the 3 groups assessed by blood pressure measurement [Change from baseline to end of the intra-operative period]

      Hypotension will be assessed by systolic blood pressure (SBP) > 20% below the baseline preoperative measurements and acquired before the epidural or any sedation has been administered and the intra-operative period

    Secondary Outcome Measures

    1. Changes between the 3 groups assessed by the spread of local anesthetic (block) effect [Change from baseline to 72 hours after discharge from the post anesthesia care unit (PACU)]

      Spread of local anesthetic (block) effect as tested by sensitivity to cold recorded every hour postoperatively and every 8 hours for the subsequent 72 hours after discharge from the PACU.

    2. Changes between the 3 groups assessed by ambulation after surgery [From post-operative (post-op) day 1 to post-op day 3]

      Ambulation on post-op day 1, post-op day 2 and post-op day 3, will be recorded by distance ambulated per 24-hour period.

    3. Changes between the 3 groups assessed by opioid usage [From day of surgery (0) to post-op day 3]

      Opioid usage data will be recorded and converted to morphine equivalents and averaged for day 0, and post-op days 1, 2, and 3 per group.

    4. Changes between the 3 groups assessed by opioid-related side effects [From day of surgery (0) to post-op day 3]

      Side effects such as pruritus, nausea/vomiting, and respiratory depression (defined as respiratory rate less than 10 breaths per minute of oxygen saturation more than 7 points lower that the patients preoperative value on room air) will be recorded.

    5. Changes between the 3 groups assessed by fluid balance [From post-op day 1 to post-op day 3]

      24 hour intake and output for the first 72 hours to assess fluid balance

    6. Changes between the 3 groups assessed by length of hospitalization [From post-op day 1 to post-op day 3]

      Length of hospitalization

    7. Changes between the 3 groups assessed by amount of days before return to oral intake status [From post-op day 1 to post-op day 3]

      Return to oral intake status

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • undergoing epidural analgesia to treat perioperative pain associated with major surgery

    • undergoing major thoracic surgery

    • undergoing major abdominal surgery

    • undergoing major orthopaedic surgery

    Exclusion Criteria:
    • sepsis

    • acute trauma

    • coagulopathy

    • preoperative hemodynamic instability

    • symptomatic coronary artery disease

    • patients from the ICU whose tracheas were intubated for any cause

    • allergies to medications in the protocol

    • primary or secondary block failure

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 UF Health Gainesville Florida United States 32610

    Sponsors and Collaborators

    • University of Florida
    • I. Heermann Anesthesia Foundation

    Investigators

    • Principal Investigator: Olga C. Nin, MD, University of Florida

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Florida
    ClinicalTrials.gov Identifier:
    NCT02722746
    Other Study ID Numbers:
    • IRB201600185
    First Posted:
    Mar 30, 2016
    Last Update Posted:
    Feb 19, 2020
    Last Verified:
    Feb 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University of Florida
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 19, 2020